{"id":474952,"date":"2024-04-04T00:00:00","date_gmt":"2024-04-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidhe0033-biopharma-paroxysmal-nocturnal-hemoglobinuria-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:30:32","modified_gmt":"2026-03-31T10:30:32","slug":"epidhe0033-biopharma-paroxysmal-nocturnal-hemoglobinuria-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidhe0033-biopharma-paroxysmal-nocturnal-hemoglobinuria-epidemiology-mature-markets\/","title":{"rendered":"Paroxysmal Nocturnal Hemoglobinuria &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of paroxysmal nocturnal hemoglobinuria (<abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts eight <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of classical <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> with bone marrow disorders.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> with aplastic anemia.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"7347\" title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr> with myelodysplastic syndrome.<\/li>\n<li>Diagnosed cases of subclinical <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>.<\/li>\n<li>Diagnosed drug-treated prevalent cases of <abbr title=\"paroxysmal nocturnal hemoglobinuria\">PNH<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-474952","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474952\/revisions"}],"predecessor-version":[{"id":475294,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474952\/revisions\/475294"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=474952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}